首页 > 最新文献

Drug Discoveries and Therapeutics最新文献

英文 中文
Long-term renoprotective effect of luseogliflozin in type 2 diabetes patients: CHikushi Anti-diabetes mellitus Trial-Lusefi (CHAT-Lu). 卢西格列净对2型糖尿病患者的长期肾保护作用:CHikushi抗糖尿病试验-卢西菲(CHAT-Lu)
IF 1.9 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-14 Epub Date: 2024-12-27 DOI: 10.5582/ddt.2024.01086
Yosuke Takamiya, Chiyori Imanaga, Ichiro Abe, Kunihisa Kobayashi, Amane Ike, Akira Kawamura, Hidenori Urata

Several sodium-glucose cotransporter 2 (SGLT2) inhibitors are known to have beneficial effects on renal function in patients with type 2 diabetes. However, the long-term effects of luseogliflozin, an SGLT2 inhibitor, remain uncertain in real-world settings. This multicenter, open-label, prospective observational study evaluated the long-term effects of luseogliflozin on renal function in Japanese patients with type 2 diabetes. Fifty-four outpatients initiated on luseogliflozin at Fukuoka University Chikushi Hospital or associated clinics were enrolled from April 2018 to December 2019, with 46 patients included in the final analysis set. The primary outcome was the change in estimated glomerular filtration rate (eGFR) from baseline to 104 weeks, and secondary outcomes included the change in eGFR at week 52 and changes in body weight and blood and urinary parameters at 52 and 104 weeks. The mean duration of diabetes was 8.1 years. Baseline eGFR was 75.8 ± 17.4 mL/min/1.73m2, and no decline in eGFR was observed from baseline to 104 weeks. Decline in eGFR was suppressed in the two groups stratified by baseline eGFR (< 60 and ≥ 60 mL/min/1.73m2). No changes were noted in urinary albumin excretion rate. Blood glucose, body weight, blood pressure, liver function, and uric acid levels showed significant improvements. There were four adverse events, but no serious adverse events closely related to luseogliflozin treatment. In type 2 diabetes patients, 2-year treatment with luseogliflozin provided beneficial metabolic effects and improved the rate of decline in eGFR, suggesting a renal protective effect.

已知几种钠-葡萄糖共转运蛋白2 (SGLT2)抑制剂对2型糖尿病患者的肾功能有有益影响。然而,luseogliflozin(一种SGLT2抑制剂)的长期效果在现实环境中仍不确定。这项多中心、开放标签、前瞻性观察性研究评估了鲁西格列净对日本2型糖尿病患者肾功能的长期影响。2018年4月至2019年12月,福冈大学千志医院(Fukuoka University Chikushi Hospital)或相关诊所的54名门诊患者开始使用卢西格列净,其中46名患者纳入最终分析集。主要结局是估计肾小球滤过率(eGFR)从基线到104周的变化,次要结局包括52周时eGFR的变化以及52周和104周时体重、血液和尿液参数的变化。糖尿病的平均病程为8.1年。基线eGFR为75.8±17.4 mL/min/1.73m2,从基线到104周未观察到eGFR下降。在基线eGFR(< 60和≥60 mL/min/1.73m2)分层的两组中,eGFR的下降受到抑制。尿白蛋白排泄率无明显变化。血糖、体重、血压、肝功能和尿酸水平均有显著改善。有4个不良事件,但没有与鲁西格列净治疗密切相关的严重不良事件。在2型糖尿病患者中,2年的鲁西格列净治疗提供了有益的代谢作用,并提高了eGFR下降的速度,表明具有肾脏保护作用。
{"title":"Long-term renoprotective effect of luseogliflozin in type 2 diabetes patients: CHikushi Anti-diabetes mellitus Trial-Lusefi (CHAT-Lu).","authors":"Yosuke Takamiya, Chiyori Imanaga, Ichiro Abe, Kunihisa Kobayashi, Amane Ike, Akira Kawamura, Hidenori Urata","doi":"10.5582/ddt.2024.01086","DOIUrl":"10.5582/ddt.2024.01086","url":null,"abstract":"<p><p>Several sodium-glucose cotransporter 2 (SGLT2) inhibitors are known to have beneficial effects on renal function in patients with type 2 diabetes. However, the long-term effects of luseogliflozin, an SGLT2 inhibitor, remain uncertain in real-world settings. This multicenter, open-label, prospective observational study evaluated the long-term effects of luseogliflozin on renal function in Japanese patients with type 2 diabetes. Fifty-four outpatients initiated on luseogliflozin at Fukuoka University Chikushi Hospital or associated clinics were enrolled from April 2018 to December 2019, with 46 patients included in the final analysis set. The primary outcome was the change in estimated glomerular filtration rate (eGFR) from baseline to 104 weeks, and secondary outcomes included the change in eGFR at week 52 and changes in body weight and blood and urinary parameters at 52 and 104 weeks. The mean duration of diabetes was 8.1 years. Baseline eGFR was 75.8 ± 17.4 mL/min/1.73m<sup>2</sup>, and no decline in eGFR was observed from baseline to 104 weeks. Decline in eGFR was suppressed in the two groups stratified by baseline eGFR (< 60 and ≥ 60 mL/min/1.73m<sup>2</sup>). No changes were noted in urinary albumin excretion rate. Blood glucose, body weight, blood pressure, liver function, and uric acid levels showed significant improvements. There were four adverse events, but no serious adverse events closely related to luseogliflozin treatment. In type 2 diabetes patients, 2-year treatment with luseogliflozin provided beneficial metabolic effects and improved the rate of decline in eGFR, suggesting a renal protective effect.</p>","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":" ","pages":"336-342"},"PeriodicalIF":1.9,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expression of c-fos in cortical neuron cultures under dynamic magnetic field is not suppressed by calcium channel blockers. 钙通道阻滞剂不抑制动态磁场下皮层神经元c-fos的表达。
IF 1.9 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-14 Epub Date: 2024-12-11 DOI: 10.5582/ddt.2024.01077
Takashi Shibata, Daisuke Ihara, Yuji Kirihara, Tohru Yagi, Akiko Tabuchi, Satoshi Kuroda

Previously, we developed a dynamic magnetic field (DMF) device using neodymium magnets that induced c-fos expression in cortical neurons, while activity-regulated cytoskeleton-associated protein (Arc), and brain-derived neurotrophic factor (BDNF) remained unaffected. The precise signal transduction pathway for c-fos induction under DMF was unclear. This study aimed to investigate the mechanism of immediate early gene (IEG) induction using calcium channel blockers (CCBs). Six experiments were conducted with cortical neurons, employing an NMDA receptor antagonist and an L-type voltage-dependent calcium channel blocker as CCBs. Neuronal cultures were exposed to DMF, CCBs, or both, and IEG expression (Arc, c-fos, BDNF) was measured through polymerase chain reaction. Results showed a tendency for increased c-fos expression with DMF exposure, which was unaffected by CCBs. In contrast, Arc and BDNF were not induced under DMF exposure but were significantly inhibited by CCBs. These findings suggest that c-fos induction under DMF involves a distinct pathway, potentially relevant to stress resistance and drug discovery.

之前,我们开发了一种动态磁场(DMF)装置,使用钕磁铁诱导皮层神经元中c-fos的表达,而活动调节的细胞骨架相关蛋白(Arc)和脑源性神经营养因子(BDNF)不受影响。DMF诱导c-fos的确切信号转导途径尚不清楚。本研究旨在探讨钙通道阻滞剂(CCBs)诱导立即早期基因(IEG)的机制。采用NMDA受体拮抗剂和l型电压依赖性钙通道阻滞剂作为CCBs,对皮质神经元进行了6次实验。将神经元培养物暴露于DMF、CCBs或两者中,并通过聚合酶链反应测量IEG表达(Arc、c-fos、BDNF)。结果显示,c-fos的表达随着DMF的暴露而增加,而CCBs则不影响c-fos的表达。相比之下,DMF对Arc和BDNF没有诱导作用,但CCBs对其有显著抑制作用。这些发现表明,DMF诱导c-fos涉及一个独特的途径,可能与抗逆性和药物发现有关。
{"title":"Expression of c-fos in cortical neuron cultures under dynamic magnetic field is not suppressed by calcium channel blockers.","authors":"Takashi Shibata, Daisuke Ihara, Yuji Kirihara, Tohru Yagi, Akiko Tabuchi, Satoshi Kuroda","doi":"10.5582/ddt.2024.01077","DOIUrl":"10.5582/ddt.2024.01077","url":null,"abstract":"<p><p>Previously, we developed a dynamic magnetic field (DMF) device using neodymium magnets that induced c-fos expression in cortical neurons, while activity-regulated cytoskeleton-associated protein (Arc), and brain-derived neurotrophic factor (BDNF) remained unaffected. The precise signal transduction pathway for c-fos induction under DMF was unclear. This study aimed to investigate the mechanism of immediate early gene (IEG) induction using calcium channel blockers (CCBs). Six experiments were conducted with cortical neurons, employing an NMDA receptor antagonist and an L-type voltage-dependent calcium channel blocker as CCBs. Neuronal cultures were exposed to DMF, CCBs, or both, and IEG expression (Arc, c-fos, BDNF) was measured through polymerase chain reaction. Results showed a tendency for increased c-fos expression with DMF exposure, which was unaffected by CCBs. In contrast, Arc and BDNF were not induced under DMF exposure but were significantly inhibited by CCBs. These findings suggest that c-fos induction under DMF involves a distinct pathway, potentially relevant to stress resistance and drug discovery.</p>","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":" ","pages":"391-396"},"PeriodicalIF":1.9,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142814591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical characteristics and aetiological analysis of combined central and pulmonary cryptococcal infection: Clinical cases. 中央和肺部合并隐球菌感染的临床特点及病原学分析。
IF 1.9 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-14 Epub Date: 2024-12-11 DOI: 10.5582/ddt.2024.01081
Yi Su, Yiyi Qian, Qingqing Wang, Yao Zhang, Bijie Hu, Jue Pan

This paper presents a summary of seven cases of combined pulmonary and central cryptococcal infection and analyses of their clinical features, treatment and prognosis. No clear correlation was identified between the intracranial cryptococcal capsular antigen titre and either the intracranial pressure or the amount of protein in the cerebrospinal fluid. Pulmonary lesions may develop in any of the lung lobes and manifest in multiple forms. Infection at the central level is predominantly meningitis. As the central cerebrospinal fluid (CSF) capsular antigen titre can be considerably elevated even when serum capsular antigen titres are markedly low, lumbar puncture and subsequent analysis are essential for every case of pulmonary cryptococcal infection. Patients with renal insufficiency or who refused intravenous treatment opted for oral fluconazole therapy, and their prognoses were favourable.

本文报告7例肺部和中央隐球菌合并感染的临床特点、治疗及预后分析。颅内隐球菌荚膜抗原滴度与颅内压或脑脊液中蛋白含量之间没有明确的相关性。肺病变可发生于任何肺叶,表现为多种形式。中央水平的感染主要是脑膜炎。由于中央脑脊液(CSF)荚膜抗原滴度可以显著升高,即使血清荚膜抗原滴度明显低,腰椎穿刺和随后的分析对每一例肺隐球菌感染都是必要的。肾功能不全或拒绝静脉注射治疗的患者选择口服氟康唑治疗,其预后良好。
{"title":"Clinical characteristics and aetiological analysis of combined central and pulmonary cryptococcal infection: Clinical cases.","authors":"Yi Su, Yiyi Qian, Qingqing Wang, Yao Zhang, Bijie Hu, Jue Pan","doi":"10.5582/ddt.2024.01081","DOIUrl":"10.5582/ddt.2024.01081","url":null,"abstract":"<p><p>This paper presents a summary of seven cases of combined pulmonary and central cryptococcal infection and analyses of their clinical features, treatment and prognosis. No clear correlation was identified between the intracranial cryptococcal capsular antigen titre and either the intracranial pressure or the amount of protein in the cerebrospinal fluid. Pulmonary lesions may develop in any of the lung lobes and manifest in multiple forms. Infection at the central level is predominantly meningitis. As the central cerebrospinal fluid (CSF) capsular antigen titre can be considerably elevated even when serum capsular antigen titres are markedly low, lumbar puncture and subsequent analysis are essential for every case of pulmonary cryptococcal infection. Patients with renal insufficiency or who refused intravenous treatment opted for oral fluconazole therapy, and their prognoses were favourable.</p>","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":" ","pages":"397-400"},"PeriodicalIF":1.9,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142814589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Shenling Guchang prescription ameliorates intestinal barrier inflammation in gestational diabetes rats via TLR4/NF-κB pathway. 参龄骨肠方通过TLR4/NF-κB通路改善妊娠期糖尿病大鼠肠道屏障炎症。
IF 1.9 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-14 Epub Date: 2024-12-12 DOI: 10.5582/ddt.2024.01066
Manling Li, Lisha Li, Xingman Liu, Tao Yang, Jingyun Gao, Anqin Wu, Zhaozhao Hua, Ling Wang

Gestational diabetes mellitus (GDM) is linked to a greater risk of various maternal and fetal complications, including the possibility of long-term metabolic issues in offspring. Our initial research suggests that the Traditional Chinese Medicine formula, Shenling Guchang prescription (SLGP), may have an impact on the gut microbiota. However, the specific mechanisms through which it affects intestinal barrier inflammation in GDM are still not fully understood. This study explored SLGP's mechanisms in GDM. Firstly, network pharmacology predicted key bioactive constituents targeting toll-like receptor 4 (TLR4)/nuclear factor-kappa B (NF-κB), guiding experimental design. Subsequently, the pregnant female rats were induced with GDM through intraperitoneal streptozotocin injection and then divided into control, model, metformin, and SLGP treatment groups. Blood samples were collected for ELISA analysis to measure levels of inflammatory markers, intestinal tissues were examined histologically using hematoxylin-eosin (HE) staining, and western blot analysis was conducted to evaluate TLR4 and NF-κB expression. Relative to control rats, model group animals exhibited significant increases in the levels of inflammatory markers (IL-1β, IL-6, TNF-α, TGF-β, CRP), as well as enhanced TLR4 and p-NF-κB p65 expression, along with intestinal histopathological changes. Treatment with SLGP notably reduced inflammatory markers and protein expression in the colonic tissue of GDM rats, leading to a decrease in histopathological damage. Overall, SLGP was found to modulate the TLR4/NF-κB pathway, resulting in enhancements in insulin resistance and a reduction in inflammatory responses in GDM rats, thereby providing protection for the intestines. This study demonstrates the potential therapeutic effectiveness of SLGP in addressing intestinal inflammation linked to GDM.

妊娠期糖尿病(GDM)与各种母体和胎儿并发症的风险增加有关,包括后代长期代谢问题的可能性。我们的初步研究表明,中药配方参灵固肠方(SLGP)可能对肠道微生物群有影响。然而,其影响GDM患者肠道屏障炎症的具体机制尚不完全清楚。本研究探讨了SLGP在GDM中的作用机制。首先,网络药理学预测toll样受体4 (TLR4)/核因子κB (NF-κB)的关键生物活性成分,指导实验设计;随后,通过腹腔注射链脲佐菌素诱导妊娠雌性大鼠GDM,并将其分为对照组、模型组、二甲双胍组和SLGP组。采集血标本,采用ELISA法检测炎症标志物水平,采用苏木精-伊红(HE)染色法检测肠组织组织学,采用western blot法检测TLR4、NF-κB表达。与对照组相比,模型组动物炎症标志物(IL-1β、IL-6、TNF-α、TGF-β、CRP)水平显著升高,TLR4、p-NF-κB p65表达增强,肠道组织病理改变。SLGP治疗显著降低GDM大鼠结肠组织炎症标志物和蛋白表达,导致组织病理学损伤减轻。总之,我们发现SLGP可以调节TLR4/NF-κB通路,导致GDM大鼠胰岛素抵抗增强,炎症反应减少,从而为肠道提供保护。本研究证明了SLGP在解决与GDM相关的肠道炎症方面的潜在治疗效果。
{"title":"Shenling Guchang prescription ameliorates intestinal barrier inflammation in gestational diabetes rats via TLR4/NF-κB pathway.","authors":"Manling Li, Lisha Li, Xingman Liu, Tao Yang, Jingyun Gao, Anqin Wu, Zhaozhao Hua, Ling Wang","doi":"10.5582/ddt.2024.01066","DOIUrl":"10.5582/ddt.2024.01066","url":null,"abstract":"<p><p>Gestational diabetes mellitus (GDM) is linked to a greater risk of various maternal and fetal complications, including the possibility of long-term metabolic issues in offspring. Our initial research suggests that the Traditional Chinese Medicine formula, Shenling Guchang prescription (SLGP), may have an impact on the gut microbiota. However, the specific mechanisms through which it affects intestinal barrier inflammation in GDM are still not fully understood. This study explored SLGP's mechanisms in GDM. Firstly, network pharmacology predicted key bioactive constituents targeting toll-like receptor 4 (TLR4)/nuclear factor-kappa B (NF-κB), guiding experimental design. Subsequently, the pregnant female rats were induced with GDM through intraperitoneal streptozotocin injection and then divided into control, model, metformin, and SLGP treatment groups. Blood samples were collected for ELISA analysis to measure levels of inflammatory markers, intestinal tissues were examined histologically using hematoxylin-eosin (HE) staining, and western blot analysis was conducted to evaluate TLR4 and NF-κB expression. Relative to control rats, model group animals exhibited significant increases in the levels of inflammatory markers (IL-1β, IL-6, TNF-α, TGF-β, CRP), as well as enhanced TLR4 and p-NF-κB p65 expression, along with intestinal histopathological changes. Treatment with SLGP notably reduced inflammatory markers and protein expression in the colonic tissue of GDM rats, leading to a decrease in histopathological damage. Overall, SLGP was found to modulate the TLR4/NF-κB pathway, resulting in enhancements in insulin resistance and a reduction in inflammatory responses in GDM rats, thereby providing protection for the intestines. This study demonstrates the potential therapeutic effectiveness of SLGP in addressing intestinal inflammation linked to GDM.</p>","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":" ","pages":"343-352"},"PeriodicalIF":1.9,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142814593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kampo medicine inducing drug-induced liver injury: A case report and systematic review. 汉布药致药物性肝损伤1例报告及系统评价。
IF 1.9 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-14 Epub Date: 2024-12-29 DOI: 10.5582/ddt.2024.01087
Akane Hoshi, Haruki Funakoshi, Yumi Otoyama, Hitoshi Yoshida, Kenji Momo

Kampo medicine, comprising various conventional crude drug products, poses challenges in identifying adverse event causality. We present a case of severe liver injury following the administration of Saibokuto and attempted to identify the likely causative crude drug inducing liver injury through a systematic literature review. A 29-year-old woman developed severe liver injury approximately two months after Saibokuto administration, necessitating steroid pulse therapy for recovery. The literature search was conducted on February 15, 2023 in Japan. Using PubMed and the "Igaku Chuo Zasshi (ICHUSHI) database," two individuals independently selected studies published between January 1997 and February 15, 2023. The search focused on studies involving human subjects, published in either English or Japanese, and specifically investigated Kampo medicines categorized as over-the-counter or prescription drugs suspected as causative agents of drug-induced liver injury (DILI). Studies on health supplements, discontinued Kampo medicines, and autoimmune hepatitis, were excluded. As it is ethically impossible to rechallenge drugs that cause liver injury, this review primarily relied on case report literature. Through the review, 37 cases (men/women: 12/25, including present case) were analyzed, including 32 reports (36 cases) from 3,055 studies that met the inclusion criteria. Notably, 65.9% of cases were associated with Scutellariae radix, with onset occurring within 45 (1-730) days and recovery within 35 (7-184) days. Our case study and literature review underscore a prevalent association between liver injury and Kampo medicines containing Scutellariae radix. Vigilant liver function monitoring, particularly within the first 2 months of administration, is recommended, especially for formulations containing Scutellariae radix.

由各种传统原料药组成的汉布药在确定不良事件因果关系方面提出了挑战。我们提出一个严重肝损伤的情况下,服用Saibokuto,并试图通过系统的文献综述,以确定可能导致肝损伤的原料药。一名29岁的女性在服用Saibokuto大约两个月后出现严重的肝损伤,需要类固醇脉冲治疗以恢复。文献检索于2023年2月15日在日本进行。使用PubMed和“Igaku Chuo zashi (ICHUSHI)数据库”,两个人独立选择了1997年1月至2023年2月15日之间发表的研究。搜索的重点是用英语或日语发表的涉及人类受试者的研究,并特别调查了被归类为非处方药或处方药的汉布药物,这些药物被怀疑是药物性肝损伤(DILI)的病原体。排除了关于保健补充剂、停用的汉布药和自身免疫性肝炎的研究。由于在伦理上不可能重新挑战导致肝损伤的药物,本综述主要依赖病例报告文献。通过回顾,我们分析了37例病例(男性/女性:12/25,包括本病例),包括来自3055项研究的32份报告(36例)符合纳入标准。值得注意的是,65.9%的病例与黄芩有关,发病时间为45(1-730)天,痊愈时间为35(7-184)天。我们的案例研究和文献综述强调了肝损伤与含有黄芩的汉布药物之间的普遍关联。建议警惕肝功能监测,特别是在给药的头2个月内,特别是含有黄芩的制剂。
{"title":"Kampo medicine inducing drug-induced liver injury: A case report and systematic review.","authors":"Akane Hoshi, Haruki Funakoshi, Yumi Otoyama, Hitoshi Yoshida, Kenji Momo","doi":"10.5582/ddt.2024.01087","DOIUrl":"10.5582/ddt.2024.01087","url":null,"abstract":"<p><p>Kampo medicine, comprising various conventional crude drug products, poses challenges in identifying adverse event causality. We present a case of severe liver injury following the administration of Saibokuto and attempted to identify the likely causative crude drug inducing liver injury through a systematic literature review. A 29-year-old woman developed severe liver injury approximately two months after Saibokuto administration, necessitating steroid pulse therapy for recovery. The literature search was conducted on February 15, 2023 in Japan. Using PubMed and the \"Igaku Chuo Zasshi (ICHUSHI) database,\" two individuals independently selected studies published between January 1997 and February 15, 2023. The search focused on studies involving human subjects, published in either English or Japanese, and specifically investigated Kampo medicines categorized as over-the-counter or prescription drugs suspected as causative agents of drug-induced liver injury (DILI). Studies on health supplements, discontinued Kampo medicines, and autoimmune hepatitis, were excluded. As it is ethically impossible to rechallenge drugs that cause liver injury, this review primarily relied on case report literature. Through the review, 37 cases (men/women: 12/25, including present case) were analyzed, including 32 reports (36 cases) from 3,055 studies that met the inclusion criteria. Notably, 65.9% of cases were associated with Scutellariae radix, with onset occurring within 45 (1-730) days and recovery within 35 (7-184) days. Our case study and literature review underscore a prevalent association between liver injury and Kampo medicines containing Scutellariae radix. Vigilant liver function monitoring, particularly within the first 2 months of administration, is recommended, especially for formulations containing Scutellariae radix.</p>","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":" ","pages":"325-335"},"PeriodicalIF":1.9,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corticosteroid dose escalation in non-ICU COVID-19 patients with worsening lung lesions reduces lesion severity without improving clinical outcomes. 非icu肺部病变加重的COVID-19患者皮质类固醇剂量增加可降低病变严重程度,但未改善临床结果。
IF 1.9 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-14 Epub Date: 2024-12-24 DOI: 10.5582/ddt.2024.01078
Qingqing Wang, Qing Miao, Yuyan Ma, Yi Su, Jue Pan, Bijie Hu

The effect of increasing corticosteroid doses on clinical outcomes and chest findings in patients with coronavirus disease (COVID-19) pneumonia and lung disease remains unknown. We aimed to investigate the effects of increasing steroid dosage on chest lesion area and clinical outcomes in patients with moderate or severe COVID-19 and progressive lung involvement on chest computed tomography (CT). A total of 105 patients with radiological progression during methylprednisolone (MP) therapy either received an increased MP dose (n = 79) or were maintained on the same MP dose (n = 26). These patients were divided into dose-increment and no-change groups according to the MP dose adjustment strategy. Clinical features, changes in CT severity scores within 7 days after steroid adjustment, and outcomes were compared between the groups. Six (7.6%) and one (3.8%) patients in the dose-increment and no-change groups, respectively, had increasing World Health Organization outcome scores 96 h after MP adjustment (P = 0.678). Length of stay [15 days (IQR: 10-24) vs. 14 days (IQR: 10-25); P = 0.994] and in-hospital death rate (7.6% vs. 3.8%; P = 0.678) showed no significant differences between the groups. Logistic regression analyses revealed that an increased MP dose was significantly associated with improvement in CT lesion area compared with no change in MP dose, but the CT lesions deteriorated subsequently (79.7% vs. 53.8%, P = 0.044). In conclusion, increasing the MP dose in patients with worsening CT findings ameliorates CT lesions but fails to prevent serious adverse outcomes.

增加皮质类固醇剂量对冠状病毒病(COVID-19)肺炎和肺部疾病患者的临床结局和胸部表现的影响尚不清楚。我们的目的是研究增加类固醇剂量对中重度COVID-19患者胸部病变面积和临床结果的影响,以及胸部计算机断层扫描(CT)对进行性肺受累的影响。共有105名在甲基强的松龙(MP)治疗期间出现放射学进展的患者接受了增加的MP剂量(n = 79)或维持相同的MP剂量(n = 26)。根据MP剂量调整策略将患者分为剂量递增组和不变组。比较两组患者的临床特征、类固醇调整后7天内CT严重程度评分的变化及结果。剂量递增组和不变组分别有6例(7.6%)和1例(3.8%)患者在MP调整96 h后世界卫生组织结局评分升高(P = 0.678)。停留时间[15天(IQR: 10-24) vs. 14天(IQR: 10-25);P = 0.994]和住院死亡率(7.6% vs. 3.8%;P = 0.678)组间差异无统计学意义。Logistic回归分析显示,与MP剂量不变相比,MP剂量增加与CT病变面积改善显著相关,但CT病变随后恶化(79.7%比53.8%,P = 0.044)。总之,在CT表现恶化的患者中,增加MP剂量可以改善CT病变,但不能预防严重的不良后果。
{"title":"Corticosteroid dose escalation in non-ICU COVID-19 patients with worsening lung lesions reduces lesion severity without improving clinical outcomes.","authors":"Qingqing Wang, Qing Miao, Yuyan Ma, Yi Su, Jue Pan, Bijie Hu","doi":"10.5582/ddt.2024.01078","DOIUrl":"10.5582/ddt.2024.01078","url":null,"abstract":"<p><p>The effect of increasing corticosteroid doses on clinical outcomes and chest findings in patients with coronavirus disease (COVID-19) pneumonia and lung disease remains unknown. We aimed to investigate the effects of increasing steroid dosage on chest lesion area and clinical outcomes in patients with moderate or severe COVID-19 and progressive lung involvement on chest computed tomography (CT). A total of 105 patients with radiological progression during methylprednisolone (MP) therapy either received an increased MP dose (n = 79) or were maintained on the same MP dose (n = 26). These patients were divided into dose-increment and no-change groups according to the MP dose adjustment strategy. Clinical features, changes in CT severity scores within 7 days after steroid adjustment, and outcomes were compared between the groups. Six (7.6%) and one (3.8%) patients in the dose-increment and no-change groups, respectively, had increasing World Health Organization outcome scores 96 h after MP adjustment (P = 0.678). Length of stay [15 days (IQR: 10-24) vs. 14 days (IQR: 10-25); P = 0.994] and in-hospital death rate (7.6% vs. 3.8%; P = 0.678) showed no significant differences between the groups. Logistic regression analyses revealed that an increased MP dose was significantly associated with improvement in CT lesion area compared with no change in MP dose, but the CT lesions deteriorated subsequently (79.7% vs. 53.8%, P = 0.044). In conclusion, increasing the MP dose in patients with worsening CT findings ameliorates CT lesions but fails to prevent serious adverse outcomes.</p>","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":" ","pages":"353-361"},"PeriodicalIF":1.9,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acupuncture and Bushen Quyu decoction improved endometrial receptivity, hormone secretion, and uterine artery blood flow for repeated implantation failure patients undergoing in vitro fertilization and embryo transfer. 针刺配合补肾祛瘀汤改善多次着床失败体外受精胚胎移植患者子宫内膜容受性、激素分泌及子宫动脉血流量。
IF 1.9 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-14 Epub Date: 2024-12-21 DOI: 10.5582/ddt.2024.01079
Qi Zhou, Lina Song, Jiahui Ma, Danyi Tang, Qing Qi, Hongmei Sun, Yan Du, Ling Wang

Acupuncture and traditional Chinese medicine (TCM) have shown certain benefits in assisted in vitro fertilization and embryo transfer (IVF-ET). In this study, we evaluated the efficacy and safety of the combination of acupuncture combined with the Bushen Quyu decoction in patients with failures of IVF-ET. This study was conducted at Shanghai Yangpu District Hospital of TCM from May to November of 2021. Patients with failed IVF-ET received either combined therapy or the routine procedure (control group). The main outcomes were implantation rate and clinical pregnancy rate. Radioimmunoassay was used to detect serum levels of estradiol (E2) and progesterone on the day of injection of human chorionic gonadotropin (hCG). The endometrial thickness, resistance index (RI), and pulsatility index (PI) of bilateral uterine arteries were measured by color Doppler ultrasound. Safety was assessed in all participants. After 3 months of treatment, the implantation rate (61.9% vs. 47.7%, P = 0.187) and clinical pregnancy rate (52.4% vs. 36.4%, P = 0.135) of patients with IVF-ET failure receiving acupuncture therapy combined with Bushen Quyu decoction appeared to be higher than those of the routine procedure group, although the increase was not statistically significant. However, the serum E2 level and endometrial thickness of patients in the combined therapy group increased significantly than those of the control group after hCG injection. The RI and PI values of bilateral uterine arteries in the combined therapy group were significantly lower than those in the control group after hCG injection. No difference of adverse events was observed between combined therapy group and control group (11.9% vs. 11.36%, P = 0.962). Acupuncture therapy combined with TCM treatment may improve endometrial receptivity and hormone secretion, and increase uterine artery blood flow.

针灸和中医在辅助体外受精和胚胎移植(IVF-ET)中显示出一定的益处。在本研究中,我们评价针刺联合补肾祛瘀汤治疗IVF-ET失败患者的疗效和安全性。本研究于2021年5月至11月在上海市杨浦区中医院进行。IVF-ET失败的患者接受联合治疗或常规手术(对照组)。主要观察着床率和临床妊娠率。采用放射免疫法检测注射人绒毛膜促性腺激素(hCG)当日血清雌二醇(E2)和孕酮水平。彩色多普勒超声检测子宫内膜厚度、双侧子宫动脉阻力指数(RI)、搏动指数(PI)。对所有参与者进行安全性评估。治疗3个月后,针灸联合补肾祛郁汤治疗IVF-ET失败患者的着床率(61.9% vs. 47.7%, P = 0.187)和临床妊娠率(52.4% vs. 36.4%, P = 0.135)均高于常规手术组,但差异无统计学意义。注射hCG后,联合治疗组患者血清E2水平和子宫内膜厚度明显高于对照组。注射hCG后,联合治疗组双侧子宫动脉RI、PI值均显著低于对照组。联合治疗组与对照组不良事件发生率差异无统计学意义(11.9% vs 11.36%, P = 0.962)。针刺疗法结合中医治疗可改善子宫内膜容受性和激素分泌,增加子宫动脉血流量。
{"title":"Acupuncture and Bushen Quyu decoction improved endometrial receptivity, hormone secretion, and uterine artery blood flow for repeated implantation failure patients undergoing in vitro fertilization and embryo transfer.","authors":"Qi Zhou, Lina Song, Jiahui Ma, Danyi Tang, Qing Qi, Hongmei Sun, Yan Du, Ling Wang","doi":"10.5582/ddt.2024.01079","DOIUrl":"10.5582/ddt.2024.01079","url":null,"abstract":"<p><p>Acupuncture and traditional Chinese medicine (TCM) have shown certain benefits in assisted in vitro fertilization and embryo transfer (IVF-ET). In this study, we evaluated the efficacy and safety of the combination of acupuncture combined with the Bushen Quyu decoction in patients with failures of IVF-ET. This study was conducted at Shanghai Yangpu District Hospital of TCM from May to November of 2021. Patients with failed IVF-ET received either combined therapy or the routine procedure (control group). The main outcomes were implantation rate and clinical pregnancy rate. Radioimmunoassay was used to detect serum levels of estradiol (E2) and progesterone on the day of injection of human chorionic gonadotropin (hCG). The endometrial thickness, resistance index (RI), and pulsatility index (PI) of bilateral uterine arteries were measured by color Doppler ultrasound. Safety was assessed in all participants. After 3 months of treatment, the implantation rate (61.9% vs. 47.7%, P = 0.187) and clinical pregnancy rate (52.4% vs. 36.4%, P = 0.135) of patients with IVF-ET failure receiving acupuncture therapy combined with Bushen Quyu decoction appeared to be higher than those of the routine procedure group, although the increase was not statistically significant. However, the serum E2 level and endometrial thickness of patients in the combined therapy group increased significantly than those of the control group after hCG injection. The RI and PI values of bilateral uterine arteries in the combined therapy group were significantly lower than those in the control group after hCG injection. No difference of adverse events was observed between combined therapy group and control group (11.9% vs. 11.36%, P = 0.962). Acupuncture therapy combined with TCM treatment may improve endometrial receptivity and hormone secretion, and increase uterine artery blood flow.</p>","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":" ","pages":"362-367"},"PeriodicalIF":1.9,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical benefits of rapid initiation of antiretroviral therapy within 14 days for newly diagnosed late-presentation people living with human immunodeficiency virus (PLWH). 新诊断的晚期人类免疫缺陷病毒(PLWH)感染者在14天内快速开始抗逆转录病毒治疗的临床益处
IF 1.9 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-01 DOI: 10.5582/ddt.2025.01011
Xiang Zhang, Hongjing Guan, Xiaoyun Di, Mengqing Li, Jingli Peng, Rentian Cai, Hongxia Wei

This study evaluated the impact of initiating antiretroviral therapy (ART) within 14 days compared to starting after 14 days in newly diagnosed, late-presenting people living with human immunodeficiency virus (PLWH). A total of 1,538 PLWH with a baseline CD4+ T-cell count < 350 cells/μL who attended our outpatient clinic from January 2017 to June 2022 were included. Participants were divided into two groups based on ART initiation timing: rapid initiation (ART within 14 days) and delayed initiation (ART after 14 days). Rapid initiation led to significantly higher virologic suppression rates at 6 months (62.5% vs. 52.7%, P < 0.05) and 1 year (81.6% vs. 72.1%, P < 0.01) compared to delayed initiation. While overall treatment retention rates were comparable, rapid initiation improved retention at 6 months for those with baseline CD4+ < 200 cells/μL and at 1 year for those with baseline CD4+ between 200 and 350 cells/μL. No significant differences in CD4+ T-cell counts or CD4/CD8 ratio were observed. A positive correlation was found between baseline viral load and time to virologic suppression, with rapid initiation of ART leading to faster suppression, especially in those with higher baseline viral loads. Multivariate analysis confirmed that ART initiation timing and baseline viral load were key determinants of virologic suppression. In conclusion, rapid ART initiation within 14 days was associated with higher virologic suppression at 6 months and 1 year. Rapid initiation of ART and lower baseline viral load were critical for virologic suppression, with improved retention for specific subgroups.

这项研究评估了在14天内开始抗逆转录病毒治疗(ART)与在14天后开始治疗对新诊断的晚期人类免疫缺陷病毒(PLWH)感染者的影响。2017年1月至2022年6月,共有1538例基线CD4+ t细胞计数< 350细胞/μL的PLWH患者在我们的门诊就诊。参与者根据ART起始时间分为两组:快速起始(14天内起始)和延迟起始(14天后起始)。与延迟起始相比,快速起始在6个月(62.5%比52.7%,P < 0.05)和1年(81.6%比72.1%,P < 0.01)时的病毒学抑制率显著高于延迟起始。尽管总体治疗保留率具有可比性,但对于基线CD4+ < 200细胞/μL的患者,快速开始治疗可在6个月时改善保留率,而对于基线CD4+在200至350细胞/μL之间的患者,快速开始治疗可在1年内改善保留率。CD4+ t细胞计数和CD4/CD8比值无显著差异。基线病毒载量与达到病毒学抑制的时间呈正相关,快速开始抗逆转录病毒治疗导致更快的抑制,特别是在那些基线病毒载量较高的患者中。多变量分析证实,ART起始时间和基线病毒载量是病毒学抑制的关键决定因素。总之,在14天内快速开始抗逆转录病毒治疗与6个月和1年时较高的病毒学抑制相关。快速开始抗逆转录病毒治疗和较低的基线病毒载量对病毒学抑制至关重要,可以改善特定亚群的保留率。
{"title":"Clinical benefits of rapid initiation of antiretroviral therapy within 14 days for newly diagnosed late-presentation people living with human immunodeficiency virus (PLWH).","authors":"Xiang Zhang, Hongjing Guan, Xiaoyun Di, Mengqing Li, Jingli Peng, Rentian Cai, Hongxia Wei","doi":"10.5582/ddt.2025.01011","DOIUrl":"https://doi.org/10.5582/ddt.2025.01011","url":null,"abstract":"<p><p>This study evaluated the impact of initiating antiretroviral therapy (ART) within 14 days compared to starting after 14 days in newly diagnosed, late-presenting people living with human immunodeficiency virus (PLWH). A total of 1,538 PLWH with a baseline CD4<sup>+</sup> T-cell count < 350 cells/μL who attended our outpatient clinic from January 2017 to June 2022 were included. Participants were divided into two groups based on ART initiation timing: rapid initiation (ART within 14 days) and delayed initiation (ART after 14 days). Rapid initiation led to significantly higher virologic suppression rates at 6 months (62.5% vs. 52.7%, P < 0.05) and 1 year (81.6% vs. 72.1%, P < 0.01) compared to delayed initiation. While overall treatment retention rates were comparable, rapid initiation improved retention at 6 months for those with baseline CD4<sup>+</sup> < 200 cells/μL and at 1 year for those with baseline CD4<sup>+</sup> between 200 and 350 cells/μL. No significant differences in CD4<sup>+</sup> T-cell counts or CD4/CD8 ratio were observed. A positive correlation was found between baseline viral load and time to virologic suppression, with rapid initiation of ART leading to faster suppression, especially in those with higher baseline viral loads. Multivariate analysis confirmed that ART initiation timing and baseline viral load were key determinants of virologic suppression. In conclusion, rapid ART initiation within 14 days was associated with higher virologic suppression at 6 months and 1 year. Rapid initiation of ART and lower baseline viral load were critical for virologic suppression, with improved retention for specific subgroups.</p>","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":"19 2","pages":"112-123"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Can the herpes zoster vaccination be a strategy against dementia? 带状疱疹疫苗能成为预防痴呆的一种策略吗?
IF 1.9 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-01 DOI: 10.5582/ddt.2025.01032
Ya-Nan Ma, Kenji Karako, Peipei Song, Ying Xia

Herpes Zoster (HZ), caused by the reactivation of the varicella-zoster virus (VZV), is a common infectious disease. Recent studies suggest a potential association between HZ and the development of dementia, particularly Alzheimer's disease and other neurodegenerative disorders. Epidemiological evidence indicates that HZ infection, especially in individuals with central nervous system involvement, may increase the risk of dementia. Pathologically, VZV may contribute to neuronal dysfunction and degeneration by inducing chronic neuroinflammation, infection-related cerebrovascular lesions, and direct central nervous system toxicity. HZ vaccines, particularly novel recombinant subunit vaccines (e.g., Shingrix), not only effectively prevent HZ but may also confer cognitive protection through mechanisms such as "trained immunity" activation and anti-inflammatory response modulation. Multiple natural experiments and retrospective cohort studies have found that HZ vaccination is significantly associated with a reduced risk of dementia, with particularly pronounced protective effects in women and older adults. Although most evidence currently stems from observational studies and is subject to potential confounding factors, the biological plausibility and consistent findings support the potential of HZ vaccination as an adjunctive strategy for dementia prevention. Future prospective randomized controlled trials are needed to further clarify the causal relationship and underlying neuroimmune mechanisms, providing a stronger evidence base for establishing scientific vaccination strategies for older adults and dementia prevention systems.

带状疱疹(HZ)是一种常见的传染病,由水痘-带状疱疹病毒(VZV)的再活化引起。最近的研究表明,HZ与痴呆症的发展,特别是阿尔茨海默病和其他神经退行性疾病之间存在潜在的联系。流行病学证据表明,HZ感染,特别是中枢神经系统受累的个体,可能增加痴呆的风险。在病理学上,VZV可能通过诱导慢性神经炎症、感染相关脑血管病变和直接中枢神经系统毒性而导致神经元功能障碍和变性。HZ疫苗,特别是新型重组亚单位疫苗(如Shingrix),不仅可以有效预防HZ,还可以通过“训练免疫”激活和抗炎反应调节等机制提供认知保护。多项自然实验和回顾性队列研究发现,HZ疫苗接种与降低痴呆风险显著相关,对妇女和老年人具有特别明显的保护作用。尽管目前大多数证据来自观察性研究,并受到潜在的混杂因素的影响,但生物学上的合理性和一致的发现支持HZ疫苗接种作为预防痴呆的辅助策略的潜力。未来的前瞻性随机对照试验需要进一步阐明因果关系和潜在的神经免疫机制,为建立科学的老年人疫苗接种策略和痴呆预防系统提供更有力的证据基础。
{"title":"Can the herpes zoster vaccination be a strategy against dementia?","authors":"Ya-Nan Ma, Kenji Karako, Peipei Song, Ying Xia","doi":"10.5582/ddt.2025.01032","DOIUrl":"https://doi.org/10.5582/ddt.2025.01032","url":null,"abstract":"<p><p>Herpes Zoster (HZ), caused by the reactivation of the varicella-zoster virus (VZV), is a common infectious disease. Recent studies suggest a potential association between HZ and the development of dementia, particularly Alzheimer's disease and other neurodegenerative disorders. Epidemiological evidence indicates that HZ infection, especially in individuals with central nervous system involvement, may increase the risk of dementia. Pathologically, VZV may contribute to neuronal dysfunction and degeneration by inducing chronic neuroinflammation, infection-related cerebrovascular lesions, and direct central nervous system toxicity. HZ vaccines, particularly novel recombinant subunit vaccines (e.g., Shingrix), not only effectively prevent HZ but may also confer cognitive protection through mechanisms such as \"trained immunity\" activation and anti-inflammatory response modulation. Multiple natural experiments and retrospective cohort studies have found that HZ vaccination is significantly associated with a reduced risk of dementia, with particularly pronounced protective effects in women and older adults. Although most evidence currently stems from observational studies and is subject to potential confounding factors, the biological plausibility and consistent findings support the potential of HZ vaccination as an adjunctive strategy for dementia prevention. Future prospective randomized controlled trials are needed to further clarify the causal relationship and underlying neuroimmune mechanisms, providing a stronger evidence base for establishing scientific vaccination strategies for older adults and dementia prevention systems.</p>","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":"19 2","pages":"124-128"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mitotic abnormalities and spindle assembly checkpoint inactivation in a cell model of Shwachman-Diamond syndrome with mutations in the Shwachman-Bodian-Diamond syndrome gene, 258+2T > C. 舒瓦赫曼-博迪恩-钻石综合征基因 258+2T > C 突变导致舒瓦赫曼-博迪恩-钻石综合征细胞模型出现有丝分裂异常和纺锤体组装检查点失活。
IF 16.4 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-15 Epub Date: 2024-10-26 DOI: 10.5582/ddt.2024.01070
Yukihiro Sera, Tsuneo Imanaka, Yusuke Iguchi, Masafumi Yamaguchi

Hematologic abnormalities are the most common symptoms of Shwachman-Diamond syndrome (SDS). The causative gene for SDS is the Shwachman-Bodian-Diamond syndrome (SBDS) gene; however, the function of SBDS and pathogenesis of each condition in SDS are largely unknown. SBDS is known to be localized at mitotic spindles and stabilizes microtubules. Previously, we demonstrated that SBDS is ubiquitinated and subsequently degraded in the mitotic phase, thereby accelerating mitotic progression. In this study, we examined mitosis in a myeloid cell model of SDS (SDS cells). 4',6-Diamidino-2-phenylindole (DAPI)-stained chromosome observation and cell cycle analysis of nocodazole-synchronized cells revealed that the SDS cells have abnormally rapid mitosis. In addition, many lagging chromosomes and micronuclei were detected. Moreover, the phosphorylation of threonine tyrosine kinase, the crucial kinase of the spindle assembly checkpoint (SAC), was suppressed. Chromosomal instability caused by SAC dysfunction may cause a variety of clinical conditions, including hematologic tumors in patients with SDS.

血液学异常是舒瓦赫曼-钻石综合征(SDS)最常见的症状。SDS 的致病基因是 Shwachman-Bodian-Diamond 综合征(SBDS)基因;然而,SBDS 的功能和 SDS 中每种病症的发病机理在很大程度上都是未知的。已知 SBDS 定位于有丝分裂轴并稳定微管。此前,我们证明了 SBDS 在有丝分裂期被泛素化并随后降解,从而加速了有丝分裂的进程。在这项研究中,我们研究了 SDS 骨髓细胞模型(SDS 细胞)中的有丝分裂。对诺贺唑同步化细胞进行4',6-二脒基-2-苯基吲哚(DAPI)染色的染色体观察和细胞周期分析发现,SDS细胞的有丝分裂异常迅速。此外,还检测到许多滞后染色体和微核。此外,苏氨酸酪氨酸激酶(纺锤体组装检查点(SAC)的关键激酶)的磷酸化受到抑制。SAC功能障碍导致的染色体不稳定性可能引发多种临床症状,包括SDS患者的血液肿瘤。
{"title":"Mitotic abnormalities and spindle assembly checkpoint inactivation in a cell model of Shwachman-Diamond syndrome with mutations in the Shwachman-Bodian-Diamond syndrome gene, 258+2T > C.","authors":"Yukihiro Sera, Tsuneo Imanaka, Yusuke Iguchi, Masafumi Yamaguchi","doi":"10.5582/ddt.2024.01070","DOIUrl":"10.5582/ddt.2024.01070","url":null,"abstract":"<p><p>Hematologic abnormalities are the most common symptoms of Shwachman-Diamond syndrome (SDS). The causative gene for SDS is the Shwachman-Bodian-Diamond syndrome (SBDS) gene; however, the function of SBDS and pathogenesis of each condition in SDS are largely unknown. SBDS is known to be localized at mitotic spindles and stabilizes microtubules. Previously, we demonstrated that SBDS is ubiquitinated and subsequently degraded in the mitotic phase, thereby accelerating mitotic progression. In this study, we examined mitosis in a myeloid cell model of SDS (SDS cells). 4',6-Diamidino-2-phenylindole (DAPI)-stained chromosome observation and cell cycle analysis of nocodazole-synchronized cells revealed that the SDS cells have abnormally rapid mitosis. In addition, many lagging chromosomes and micronuclei were detected. Moreover, the phosphorylation of threonine tyrosine kinase, the crucial kinase of the spindle assembly checkpoint (SAC), was suppressed. Chromosomal instability caused by SAC dysfunction may cause a variety of clinical conditions, including hematologic tumors in patients with SDS.</p>","PeriodicalId":47494,"journal":{"name":"Drug Discoveries and Therapeutics","volume":" ","pages":"283-289"},"PeriodicalIF":16.4,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142510348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Drug Discoveries and Therapeutics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1